Analytical Data
-
Gene name
PSMA1
- Application
-
Alternative Names
NOTCH3;Neurogenic locus notch homolog Protein 3
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P25786
-
Expression Region
1-263aa
-
AA Sequence
MGSSHHHHHH SSGLVPRGSH MGSMFRNQYD NDVTVWSPQG RIHQIEYAME AVKQGSATVG LKSKTHAVLV ALKRAQSELA AHQKKILHVD NHIGISIAGL TADARLLCNF MRQECLDSRF VFDRPLPVSR LVSLIGSKTQ IPTQRYGRRP YGVGLLIAGY DDMGPHIFQT CPSANYFDCR AMSIGARSQS ARTYLERHMS EFMECNLNEL VKHGLRALRE TLPAEQDLTT KNVSIGIVGK DLEFTIYDDD DVSPFLEGLE ERPQRKAQPA QPADEPAEKA DEPMEH
-
Molecular Weight
32 kDa i
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
PSMA1 (Proteasome Subunit Alpha Type-1) is a crucial component of the 26S proteasome, a complex responsible for degrading ubiquitinated proteins, thus playing a vital role in maintaining cellular homeostasis and regulating various cellular processes, including the cell cycle, apoptosis, and antigen processing. Research into PSMA1 has gained significant traction due to its implications in various diseases, particularly cancer, where dysregulation of protein degradation pathways can contribute to tumorigenesis and drug resistance. Additionally, PSMA1 is implicated in neurodegenerative disorders, as the accumulation of misfolded proteins can lead to cellular dysfunction. Understanding the structure, function, and regulation of PSMA1 is essential for developing targeted therapies that may restore proteostasis and enhance the efficacy of existing treatments. Recent advancements in recombinant protein technology have enabled the production of PSMA1 in sufficient quantities for functional studies and structural characterization, paving the way for detailed investigations into its role in disease. Furthermore, PSMA1 holds promise as a potential biomarker and therapeutic target, particularly in the context of targeted proteasome inhibitors that are currently being explored in clinical settings. Overall, ongoing research into PSMA1 is crucial for elucidating its biological significance and therapeutic potential in various pathological conditions.
